Fishman Retires from Novartis; New Research Head Appointed
This article was originally published in Scrip
Novartis AG has named Dr. James E. Bradner president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the company's executive committee – effective March 1, 2016. Bradner will replace Dr. Mark C. Fishman, who is retiring after 13-years leading Novartis's discovery and early clinical development efforts.
You may also be interested in...
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
In the most recent installment of In Vivo's VC Playbook column, former Amgen R&D lead Sean Harper talks exclusively about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.